An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and thymosin beta-4. The panel turned down emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, Kennedy called for expanded access to controversial peptides, calling for reduced restrictions. The vote reflects a broader shift in how policymakers view specialty peptide therapies, which have drawn growing interest from patients seeking alternatives to conventional drugs. Scientists say peptide treatments could change approaches to resistant infections, though concerns about quality persist. The committee's endorsement of six peptides paves the way for more broad prescribing, even as watchdogs warn of limited evidence. Sector observers note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on particular peptide candidates.